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EFFECTIVENESS OF PRAMIPEXOLE INTHETREATMENT OF
RLS ANDTHE EFFECT ON WORK PRODUCTIVITY:
A 12-WEEKS NON-INTERVENTIONALTRIAL IN PATIENTS
WITH PRIMARY RESTLESS LEGS SYNDROM (RLS)
Eisensehr I1, Möller C2, Köster J2, Brüggenjürgen B3
1Neurologie in der Sendlinger Straße, München, Germany,
2Boehringer-Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein,
Germany, 3Charité University Medical Center, Berlin, Germany
OBJECTIVES: To evaluate the effectiveness of pramipexole
treatment in patients with primary Restless Legs Syndrome (RLS)
and, secondarily, the effect on work productivity impairment
associated with RLS. METHODS: This was an open-label, 12
week-prospective, non-controlled, non-interventional trial in
patients with primary moderate to severe RLS being treated with
the non-ergot dopamine agonist pramipexole by general practi-
tioners and internists across Germany under routine conditions.
Work productivity impairment was assessed by the Work Pro-
ductivity and Activity Impairment Questionnaire (WPAI), RLS
severity was measured by the International RLS Study Group
Rating Scale (IRLS). RESULTS: A total of 2,546 patients suffer-
ing from moderate to severe RLS were evaluated at 904 sites. The
mean age of the patients was 64.8 years and 67.8% were female.
Median treatment duration was 92 days. Patients were starting
with a median initial pramipexole dose of 0.088 mg/d, were
ﬂexibly titrated and had a ﬁnal maintenance dose of 0.35 mg/d.
RLS severity was signiﬁcantly improved: IRLS mean score was
25.7 at baseline and 9.6 at the ﬁnal visit. From the total popu-
lation 539 patients (21.2%) were in paid labour. The mean age of
this sub-population was 52.1 years; 58.1% were female. Impair-
ment while working due to RLS was reduced by 30% (median) in
a subgroup of 436 patients, who reported impairment at base-
line. In 162 patients reporting ‘Missing from work due to health
problems’ at baseline, a 6.1 hours/week (mean) reduction at the
ﬁnal visit was assessed by the WPAI, which translates into an
average reduction in productivity loss for working RLS patients
of €1642 in Germany. CONCLUSION: Pramipexole showed to
be highly effective in the treatment of RLS in routine care, as
substantiated by IRLS. Work productivity was substantially
increased and impairment while working due to RLS-symptoms
was reduced in patients being in paid labour.
OSTEOPOROSIS—Clinical Outcomes Studies
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EFFICACY OF ZOLEDRONIC ACID RELATIVETO OTHER
TREATMENTS FORVERTEBRAL FRACTURES IN
OSTEOPOROSIS: RESULTS OF A BAYESIAN MIXED
TREATMENT COMPARISON
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OBJECTIVES: To evaluate the efﬁcacy of zoledronic acid relative
to other anti-resorptive interventions regarding the prevention of
vertebral fractures in postmenopausal women with osteoporosis.
METHODS: Twelve randomized placebo controlled trials inves-
tigating the effects of zoledronic acid (1 study), alendronate (3),
risedronate (2), ibandronate (1), etidronate (1), calcitonin (1),
ralixofene (1), or strontium ranelate (2) in terms of fractures with
a follow-up of 3 years (or 2 years if used for registration pur-
poses) were identiﬁed with a systematic literature search. The
endpoint of interest was morphometric vertebral fractures.
Results of all trials were analyzed simultaneously with a Bayesian
mixed treatment comparison (MTC). MTC is an extension of
traditional meta-analysis by including multiple different pair-
wise comparisons across the range of different interventions.
With MTC the relative treatment effect of one intervention to
another can be obtained in the absence of head-to-head evidence.
In contrast to a frequentist approach, a Bayesian analysis allows
for direct probabilistic inferences. Outcomes were analyzed using
a random effects model. RESULTS: There is a 73.6% probability
that zoledronic acid shows the greatest reduction in vertebral
fractures of all interventions compared, followed by etidronate
(23.2% probability) and ibandronate (1.8%). Zoledronic acid
showed an OR of 0.28 (95% Credible Interval 0.19–0.40) rela-
tive to placebo, an OR of 0.62 relative to etidronate, and an OR
of 0.55 relative to ibandronate. Corresponding probabilities that
zoledronic provides a greater vertebral risk reduction are 99.9%,
79.6%, and 98.9% compared to placebo, etidronate, and iban-
dronate, respectively. Similar comparisons are under investiga-
tion for other fracture endpoints. CONCLUSION: Of the
available treatments for osteoporosis, zoledronic acid is one of
the treatments that provide greatest fracture risk reductions in
general. Furthermore zoledronic acid showed greatest reductions
regarding vertebral fractures.
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OBJECTIVES: Regarding intracapsular femoral neck fractures,
the main focus of research is the correlation between fracture-
related complications and prognostic factors. The purpose of this
study was to evaluate the correlation between complications
required surgery (fracture-related treatment) and, among others,
several less extensively investigated prognostic factors (day of
surgery, co-morbidities, hospital type) in a 2-year period follow-
ing internal ﬁxation in young adults with intracapsular femoral
neck fracture. METHODS: Retrospective analysis of femoral
neck fractures occurred in Hungary in 2000, based on data
obtained from the National Health Fund Administration. The
data were validated and completed by a questionnaire carried out
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in all 60 institutions enrolled. Patients with polytrauma were not
included into the study. The effects of prognostic factors were
analysed by uni- and multivariate logistic regression (p″T0.05)
in three groups: 1) all fracture-related treatments; 2) non-
prosthetic; and 3) prosthetic treatments. RESULTS: Out of 413
patients, 17.92% required further fracture-related treatment. In
7.75% non-prosthetic, and in 10.17% prosthetic treatment was
performed. We demonstrated the odds ratios by multivariate
regression analysis according to risk factors [95% conﬁdence
interval, CI] are also given. Fracture displacement ORf2.243,
CI:[1.036–4.858] weekend surgery ORf2.347, CI:[1.049–5.248],
infections ORf3.681, CI:[1.172–11.55], central nervous system-
related co-morbidities ORf3.639, CI:[1.421–9.318] and the
county hospital level of management ORf2.356, CI:[0.997–
5.568] were associated with signiﬁcantly increased risk for
further surgery. CONCLUSION: To reduce the inﬂuence of risk
factors, standardization of the substantive traumatologic and
orthopedic professional guidelines, as well as the introduction
of common orthopedic-trauma patient care (British model) are
suggested. To achieve high-quality standardized patient manage-
ment, personal and material conditions are required to be acces-
sible every day of the week. In the presence of co-morbidities,
reduction of their harmful effects should be a major consider-
ation by focusing on the patient both in the peri- and postopera-
tive periods.
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OBJECTIVES: The aim of the present study was to investigate
the relationship between the delay of deﬁnitive surgical treat-
ment and mortality rates occurring within 30 days post-injury
in patients aged 60 or older with femoral neck fracture.
METHODS: Data were obtained from the database of the
National Health Insurance Fund and from the questionnaire
survey carried out by the institutions providing the treatment.
Logistic regression analysis was performed to analyse the cor-
relation between mortality risks within 30 days and delayed
surgery in patients operated at 12–24 h, 24–48 h or after 48 h
post-injury in comparison with mortality risks associated with
early (within 12 h) treatment. RESULTS: The number of
patients meeting the case deﬁnition criteria was 3777 with the
average age of 77.97 years. Mortality rates in four groups were
7.7%, 10.5%, 10.5% and 9.4%, respectively. According to
multiple regression analysis, all three groups (12–24 h, 24–48 h
and the over 48 h) showed a trend to increased mortality risks
but this was not statistically signiﬁcant (OR12–24 h = 1.301
CI12–24 h: 0.945–1.791, p = 0.106; OR24–48 h = 1.384 CI24–
48 h: 0.932–2.056, p = 0.108; OR48 h <= .246 CI48 h <:
0.950–1.635, p = 0.113). Sex, age and accompanying diseases
signiﬁcantly inﬂuenced early mortality, while early post-
operative complications did not have a signiﬁcant impact on the
mortality risks. CONCLUSION: The results of the present
study indicate the importance of early surgery in the treatment
of femoral neck fractures in order to decrease early mortality
associated with the disease in the elderly populations. Our
results highlight the importance of further evaluating the
reasons behind the delay in the surgical treatment (problems
during treatment, difﬁculties in surgical access, co-morbidity
etc.), especially in cases when surgery is performed with a 24 h
or longer post-injury delay in order to determine factors that
inﬂuence the prognostic signiﬁcance of surgical delay in the case
of different patient groups.
OSTEOPOROSIS—Cost Studies
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OBJECTIVES: With at least 150,000 osteoporotic fractures in
France, annual cost for osteoporosis consequences was estimated
to about €600 millions. Poor diagnosis rate led French authori-
ties to decide reimbursement of bone mineral densitometry
(BMD) for osteoporosis high risk population in July 2006 (i.e.
postmenopausal women with at least one risk factor as deﬁned
by the National Union of the Health Insurance Services). Our
study was aimed to estimate the prevalence of osteoporosis risk
factors so as to assess the economic impact of this case-ﬁnding
strategy. METHODS: This cross-sectional epidemiological
survey was carried out within a representative population of
women aged 45 years and over constituted using a stratiﬁed
random sampling method (age, sex, socio-professional group,
and employment status). Face-to-face home interviews deter-
mined eligibility of women for BMD-screening and whether they
had underwent a BMD and received a diagnosis of osteoporosis.
Direct costs were assessed from the perspective of the health care
providers (i.e. BMD and physician consultation: 39.96€ and
18.60€ respectively). RESULTS: In our sample, 79.6% (2081) of
women were menopaused. 51.8% of them were eligible for
BMD-screening and 11.6%were already diagnosed by BMD with
osteoporosis. Among the diagnosed women, a third (31.0%)
didn’t have any risk factors and would not be eligible for the
screening. Based on these results, number of French eligible
women for BMD-screening would be about 5.8 millions associ-
ated with a total cost of €342 millions. Women diagnosed by
BMD were 1.3 million and could also achieve 2.3 millions rep-
resenting a cost per patient screened of 165€. CONCLUSION:
According to this study, the French case-ﬁnding strategy for
postmenopausal osteoporosis would cost €342 millions and
would lead to treat an additional one million patients.
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LITERATURE REVIEW ONTHE COSTS OF NON-COMPLIANCE
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OBJECTIVES: Medication compliance is a signiﬁcant factor con-
tributing to the clinical- and cost-effectiveness of therapy. This
study aimed to investigate the evidence on the overall cost of
non-compliance with medication, taking osteoporosis therapy as
an example. METHODS: The speciﬁc question addressed was
“What are the direct medical health care costs of non-compliance
and non-persistence in osteoporosis”. A Literature review was
conducted to search for publications presenting work under the
broad terms “costs”, “compliance/persistence” and “osteoporo-
sis”. The databases searched were Medline, EMBASE, and the
Cochrane Library. The listings were then appraised to identify
those papers relevant to the study question and for inclusion in
A394 Abstracts
